Litigation
Celgene Corporation v. Par Pharmaceutical, Inc.
terminated2:17-cv-03159
- Court
- D.N.J.
- Filed
- 2017-05-04
- Terminated
- 2019-02-06
Patents at issue (1)
Plaintiffs (1)
Defendants (1)
Summary
Celgene filed a 35 U.S.C. §271 action against Par Pharmaceutical and others in D.N.J. involving the '428 patent. The case was terminated on Feb. 6, 2019, consistent with the Pomalyst ANDA settlements, though the disposition was not confirmed in the retrieved sources.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
In the news
What the press has reported about this case, summarized with links to the source articles.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).